BMO Sticks With Outperform on Celestica Ahead of Q4 Results, Cites TPU Upside and Hyperscaler Demand
BMO Capital has maintained its Outperform rating and $370 price target on Celestica (CLS) ahead of the company's fourth-quarter 2025 results, citing a stronger outlook for the company's TPU business and ongoing hyperscaler capital expenditure as potential catalysts for upside into fiscal 2026. Celestica has posted double-digit revenue growth and su…